CapsoVision, Inc. (CV)

Market Cap	326.81M +48.3%
Revenue (ttm)	13.89M +11.0%
Net Income	-29.83M
EPS	-0.62
Shares Out	50.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	160,766
Open	6.46
Previous Close	6.45
Day's Range	6.40 - 6.65
52-Week Range	4.50 - 15.37
Beta	n/a
Analysts	Strong Buy
Price Target	9.50 (+45.48%)
Est. Earnings	Nov 12, 2026

About CV

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 2, 2025
• Employees: 99
• Stock Exchange: Nasdaq
• Ticker Symbol: CV
• Website: https://capsovision.com

Financial Performance

In 2025, CapsoVision's revenue was $13.55 million, an increase of 15.29% compared to the previous year's $11.76 million. Losses were -$25.32 million, 27.2% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for CV stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 45.48% from the latest price.

Price Target

$9.5

(45.48% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 17, 2026

Data Sources Report a data error